Erdafitinib not checked
Johnson & Johnson (Janssen) · JNJ-42756493 · G-024
FollowEvery change as it happens, and a Monday email
Trials
6 active
17 in total · 8 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
- How it’s given
- “Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.”In the company’s words, NCT03390504 on ClinicalTrials.gov
- Tested for
- Urothelial Cancer (2 trials), Urothelial Carcinoma, Non-Muscle Invasive Bladder Neoplasms
- Main trialPhase 3
- “The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).”In the company’s words, NCT03390504 on ClinicalTrials.gov
- Other names
- JNJ-42756493 · G-024
Other drugs for Urothelial Cancer
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- Disitamab vedotinPfizer · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- CetrelimabJohnson & Johnson (Janssen) · Phase 3
- TAR-200Johnson & Johnson (Janssen) · Phase 3
Coming up1
- 30 Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Apr 2024 | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | |
| Phase 2Active, not recruiting | 15 Sep 2022 | An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer | |
| Phase 1/2Active, not recruiting | 30 Sep 2022 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | |
| Phase 1/2Active, not recruiting | 30 Mar 2028 | Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | |
| Phase 2Completed | 12 Oct 2021 | A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma | |
| Phase 2Completed | 4 Dec 2023 | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations | |
| Phase 2Completed | 12 Jul 2024 | A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | |
| Phase 1/2Completed | 13 May 2019 | Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma | |
| Phase 1Completed | Aug 2015 | A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets | |
| Phase 1Completed | 5 Jul 2017 | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma | |
| Phase 1Completed | 1 Sep 2017 | A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants | |
| Phase 1Terminated | 22 Dec 2020 | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib | |
| Phase 1Completed | 14 Jun 2022 | A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants | |
| Phase 1Completed | 4 Jul 2022 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers | |
| Phase 1Completed | 11 Mar 2025 | A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer | |
| Phase 2Authorised | not given | A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial) | |
| Phase 2Authorised | not given | A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026